Antibody Fragments Market Size, Share, Trends, Growth Outlook

Antibody Fragments Market is estimated to increase at a growth rate of 6.3% CAGR over the forecast period from 2024 to 2030.

The Antibody Fragments Market study analyzes and forecasts the market size across 6 regions and 24 countries for diverse segments including By Specificity, Monoclonal Antibodies, Polyclonal Antibodies), By Type (FAB, scFv, sdAb, Others), By Therapy (Monoclonal Antibodies, PAB), By Application (Cancer, Immunodeficiency, Others).

An Introduction to Antibody Fragments Market in 2024

The Antibody Fragments Market in 2024 is witnessing steady growth, driven by the increasing demand for next-generation antibody formats, advancements in protein engineering, and the growing interest in smaller, targeted therapeutics with improved tissue penetration and pharmacokinetic properties. Antibody fragments represent a diverse class of engineered antibody derivatives, including single-chain variable fragments (scFvs), Fab fragments, and nanobodies, designed to retain antigen-binding specificity while offering advantages such as reduced size, enhanced tissue penetration, and rapid clearance from circulation. With advancements in phage display technology, protein optimization platforms, and conjugation strategies, the market offers a variety of antibody fragment formats, engineered for targeted drug delivery, imaging applications, and diagnostic assays across various disease indications. Moreover, emerging research into bispecific antibody fragments, multispecific scaffolds, and novel fusion proteins holds promise for further expanding the therapeutic and diagnostic utility of antibody fragments and addressing unmet medical needs in oncology, immunology, and infectious diseases.

Antibody Fragments Market Trend: Rising Interest in Antibody Fragment Therapeutics

A prominent trend in the Antibody Fragments market is the increasing interest and adoption of antibody fragment therapeutics in drug development. Antibody fragments, such as single-chain variable fragments (scFv), Fab fragments, and nanobodies, offer several advantages over full-length antibodies, including improved tissue penetration, rapid clearance, and reduced immunogenicity. These properties make antibody fragments attractive candidates for therapeutic applications in various disease areas, including oncology, immunology, and infectious diseases. As a result, pharmaceutical companies and biotechnology firms are increasingly exploring the development of antibody fragment-based drugs, driving the demand for research, development, and manufacturing services related to antibody fragments.

Antibody Fragments Market Driver: Growing Demand for Targeted Therapeutics

A key driver fueling the Antibody Fragments market is the growing demand for targeted therapeutics with enhanced efficacy and safety profiles. Antibody fragments offer the potential for precise targeting of disease-associated antigens while minimizing off-target effects and systemic toxicity. This targeted approach aligns with the industry's shift towards personalized medicine and the development of therapies tailored to specific patient populations or disease subtypes. Additionally, the versatility of antibody fragments allows for the engineering of novel formats with optimized pharmacokinetics and tissue-specific targeting, further expanding their utility in therapeutic applications. As pharmaceutical companies seek to address unmet medical needs and improve patient outcomes, the demand for antibody fragment-based therapeutics is expected to continue driving growth in the market.

Antibody Fragments Market Opportunity: Innovation in Antibody Fragment Engineering and Optimization

An opportunity in the Antibody Fragments market lies in the innovation and optimization of antibody fragment engineering technologies and platforms. With advancements in protein engineering, structural biology, and computational modeling, there is an opportunity to develop novel antibody fragment formats with enhanced properties, such as improved stability, affinity, and specificity. Additionally, optimization of manufacturing processes, such as cell line development, expression systems, and purification methods, can lead to increased yields, reduced production costs, and improved scalability of antibody fragment production. Furthermore, there is an opportunity to explore novel applications of antibody fragments beyond traditional therapeutics, such as diagnostic imaging agents, targeted drug delivery systems, and research tools for drug discovery. By investing in research and development efforts aimed at enhancing the performance and versatility of antibody fragments, companies can capitalize on the growing demand for innovative biologics and drive further expansion in the Antibody Fragments market.

Antibody Fragments Market Segmentation

By Specificity
Monoclonal Antibodies
Polyclonal Antibodies
By Type
FAB
scFv
sdAb
Others
By Therapy
Monoclonal Antibodies
-Praxbind (idarucizumab)
-Ranibizumab (Lucentis)
-Certolizumab pegol (Cimzia)
-Iodine (1311) Metuximab/ Licartin
-Beovu (brolucizumab-dbll)
-Cablivi (caplacizumab-yhdp)
-Blinatumomab/
PAB
-CroFab
-Anavip
-Anascorp
-Botulism Antitoxin Heptavalent (HBAT)
-Digibind
-DigiFab
Pipeline
-AFM13
-HPN-424
-MGD007
-Tebotelimab (MGD013)
-Bentracimab (PB2452)
-Flotetuzumab (MGD006)
-AK104
-Ozoralizumab
-Sonelokimab (ALX0761)
By Application
Cancer
Immunodeficiency
Others
Geographical Analysis
North America (United States, Canada, Mexico)
Europe (Germany, France, United Kingdom, Spain, Italy, Rest of Europe)
Asia Pacific (China, India, Japan, South Korea, Rest of Asia Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East and Africa (Saudi Arabia, UAE, Rest of Middle East, South Africa, Egypt, Rest of Africa)

 

Antibody Fragments Market Companies

AbbVie Inc
Albynx
Bristol-Myers Squibb Company
Genentech Inc
Johnson & Johnson Private Ltd
Lilly
Novartis AG
Pfizer Inc

 

 

Reasons to Buy the Antibody Fragments Market Study

• Deepen your industry insights and navigate uncertainties for strategy formulation, CAPEX, and Operational decisions
• Gain access to detailed insights on the Antibody Fragments Market, encompassing current market size, growth trends, and forecasts till 2030.
• Access detailed competitor analysis, enabling competitive advantage through a thorough understanding of market players, strategies, and potential differentiation opportunities
• Stay ahead of the curve with insights on technological advancements, innovations, and upcoming trends
• Identify lucrative investment avenues and expansion opportunities within the Antibody Fragments Market industry, guided by robust, data-backed analysis.
• Understand regional and global markets through country-wise analysis, regional market potential, regulatory nuances, and dynamics
• Execute strategies with confidence and speed through information, analytics, and insights on the industry value chain
• Corporate leaders, strategists, financial experts, shareholders, asset managers, and governmental representatives can make long-term planning scenarios and build an integrated and timely understanding of market dynamics
• Benefit from tailored solutions and expert consultation based on report insights, providing personalized strategies aligned with specific business needs.

 

TABLE OF CONTENTS

1 Introduction to 2024 Antibody Fragments Market
1.1 Market Overview
1.2 Quick Facts
1.3 Scope/Objective of the Study
1.4 Market Definition
1.5 Countries and Regions Analyzed
1.6 Units, Currency, and Conversions
1.7 Industry Value Chain

2 Research Methodology
2.1 Market Size Estimation
2.2 Sources and Research Methodology
2.3 Data Triangulation
2.4 Assumptions and Limitations

3 Executive Summary
3.1 Global Antibody Fragments Market Size Outlook, $ Million, 2021 to 2030
3.2 Antibody Fragments Market Outlook by Type, $ Million, 2021 to 2030
3.3 Antibody Fragments Market Outlook by Product, $ Million, 2021 to 2030
3.4 Antibody Fragments Market Outlook by Application, $ Million, 2021 to 2030
3.5 Antibody Fragments Market Outlook by Key Countries, $ Million, 2021 to 2030

4 Market Dynamics
4.1 Key Driving Forces of Antibody Fragments Market Industry
4.2 Key Market Trends in Antibody Fragments Market Industry
4.3 Potential Opportunities in Antibody Fragments Market Industry
4.4 Key Challenges in Antibody Fragments Market Industry

5 Market Factor Analysis
5.1 Competitive Landscape
5.1.1 Global Antibody Fragments Market Share by Company (%), 2023
5.1.2 Product Offerings by Company
5.2 Porter’s Five Forces Analysis

6 Growth Outlook Across Scenarios
6.1 Growth Analysis-Case Scenario Definitions
6.2 Low Growth Scenario Forecasts
6.3 Reference Growth Scenario Forecasts
6.4 High Growth Scenario Forecasts

7 Global Antibody Fragments Market Outlook By Segments
7.1 Antibody Fragments Market Outlook by Segments
By Specificity
Monoclonal Antibodies
Polyclonal Antibodies
By Type
FAB
scFv
sdAb
Others
By Therapy
Monoclonal Antibodies
-Praxbind (idarucizumab)
-Ranibizumab (Lucentis)
-Certolizumab pegol (Cimzia)
-Iodine (1311) Metuximab/ Licartin
-Beovu (brolucizumab-dbll)
-Cablivi (caplacizumab-yhdp)
-Blinatumomab/
PAB
-CroFab
-Anavip
-Anascorp
-Botulism Antitoxin Heptavalent (HBAT)
-Digibind
-DigiFab
Pipeline
-AFM13
-HPN-424
-MGD007
-Tebotelimab (MGD013)
-Bentracimab (PB2452)
-Flotetuzumab (MGD006)
-AK104
-Ozoralizumab
-Sonelokimab (ALX0761)
By Application
Cancer
Immunodeficiency
Others

8 North America Antibody Fragments Market Analysis And Outlook To 2030
8.1 Introduction to North America Antibody Fragments Markets in 2024
8.2 North America Antibody Fragments Market Size Outlook by Country, 2021-2030
8.2.1 United States
8.2.2 Canada
8.2.3 Mexico
8.3 North America Antibody Fragments Market size Outlook by Segments, 2021-2030
By Specificity
Monoclonal Antibodies
Polyclonal Antibodies
By Type
FAB
scFv
sdAb
Others
By Therapy
Monoclonal Antibodies
-Praxbind (idarucizumab)
-Ranibizumab (Lucentis)
-Certolizumab pegol (Cimzia)
-Iodine (1311) Metuximab/ Licartin
-Beovu (brolucizumab-dbll)
-Cablivi (caplacizumab-yhdp)
-Blinatumomab/
PAB
-CroFab
-Anavip
-Anascorp
-Botulism Antitoxin Heptavalent (HBAT)
-Digibind
-DigiFab
Pipeline
-AFM13
-HPN-424
-MGD007
-Tebotelimab (MGD013)
-Bentracimab (PB2452)
-Flotetuzumab (MGD006)
-AK104
-Ozoralizumab
-Sonelokimab (ALX0761)
By Application
Cancer
Immunodeficiency
Others

9 Europe Antibody Fragments Market Analysis And Outlook To 2030
9.1 Introduction to Europe Antibody Fragments Markets in 2024
9.2 Europe Antibody Fragments Market Size Outlook by Country, 2021-2030
9.2.1 Germany
9.2.2 France
9.2.3 Spain
9.2.4 United Kingdom
9.2.4 Italy
9.2.5 Russia
9.2.6 Norway
9.2.7 Rest of Europe
9.3 Europe Antibody Fragments Market Size Outlook By Segments, 2021-2030
By Specificity
Monoclonal Antibodies
Polyclonal Antibodies
By Type
FAB
scFv
sdAb
Others
By Therapy
Monoclonal Antibodies
-Praxbind (idarucizumab)
-Ranibizumab (Lucentis)
-Certolizumab pegol (Cimzia)
-Iodine (1311) Metuximab/ Licartin
-Beovu (brolucizumab-dbll)
-Cablivi (caplacizumab-yhdp)
-Blinatumomab/
PAB
-CroFab
-Anavip
-Anascorp
-Botulism Antitoxin Heptavalent (HBAT)
-Digibind
-DigiFab
Pipeline
-AFM13
-HPN-424
-MGD007
-Tebotelimab (MGD013)
-Bentracimab (PB2452)
-Flotetuzumab (MGD006)
-AK104
-Ozoralizumab
-Sonelokimab (ALX0761)
By Application
Cancer
Immunodeficiency
Others

10 Asia Pacific Antibody Fragments Market Analysis And Outlook To 2030
10.1 Introduction to Asia Pacific Antibody Fragments Markets in 2024
10.2 Asia Pacific Antibody Fragments Market Size Outlook by Country, 2021-2030
10.2.1 China
10.2.2 India
10.2.3 Japan
10.2.4 South Korea
10.2.5 Indonesia
10.2.6 Malaysia
10.2.7 Australia
10.2.8 Rest of Asia Pacific
10.3 Asia Pacific Antibody Fragments Market size Outlook by Segments, 2021-2030
By Specificity
Monoclonal Antibodies
Polyclonal Antibodies
By Type
FAB
scFv
sdAb
Others
By Therapy
Monoclonal Antibodies
-Praxbind (idarucizumab)
-Ranibizumab (Lucentis)
-Certolizumab pegol (Cimzia)
-Iodine (1311) Metuximab/ Licartin
-Beovu (brolucizumab-dbll)
-Cablivi (caplacizumab-yhdp)
-Blinatumomab/
PAB
-CroFab
-Anavip
-Anascorp
-Botulism Antitoxin Heptavalent (HBAT)
-Digibind
-DigiFab
Pipeline
-AFM13
-HPN-424
-MGD007
-Tebotelimab (MGD013)
-Bentracimab (PB2452)
-Flotetuzumab (MGD006)
-AK104
-Ozoralizumab
-Sonelokimab (ALX0761)
By Application
Cancer
Immunodeficiency
Others

11 South America Antibody Fragments Market Analysis And Outlook To 2030
11.1 Introduction to South America Antibody Fragments Markets in 2024
11.2 South America Antibody Fragments Market Size Outlook by Country, 2021-2030
11.2.1 Brazil
11.2.2 Argentina
11.2.3 Rest of South America
11.3 South America Antibody Fragments Market size Outlook by Segments, 2021-2030
By Specificity
Monoclonal Antibodies
Polyclonal Antibodies
By Type
FAB
scFv
sdAb
Others
By Therapy
Monoclonal Antibodies
-Praxbind (idarucizumab)
-Ranibizumab (Lucentis)
-Certolizumab pegol (Cimzia)
-Iodine (1311) Metuximab/ Licartin
-Beovu (brolucizumab-dbll)
-Cablivi (caplacizumab-yhdp)
-Blinatumomab/
PAB
-CroFab
-Anavip
-Anascorp
-Botulism Antitoxin Heptavalent (HBAT)
-Digibind
-DigiFab
Pipeline
-AFM13
-HPN-424
-MGD007
-Tebotelimab (MGD013)
-Bentracimab (PB2452)
-Flotetuzumab (MGD006)
-AK104
-Ozoralizumab
-Sonelokimab (ALX0761)
By Application
Cancer
Immunodeficiency
Others

12 Middle East And Africa Antibody Fragments Market Analysis And Outlook To 2030
12.1 Introduction to Middle East and Africa Antibody Fragments Markets in 2024
12.2 Middle East and Africa Antibody Fragments Market Size Outlook by Country, 2021-2030
12.2.1 Saudi Arabia
12.2.2 UAE
12.2.3 Oman
12.2.4 Rest of Middle East
12.2.5 Egypt
12.2.6 Nigeria
12.2.7 South Africa
12.2.8 Rest of Africa
12.3 Middle East and Africa Antibody Fragments Market size Outlook by Segments, 2021-2030
By Specificity
Monoclonal Antibodies
Polyclonal Antibodies
By Type
FAB
scFv
sdAb
Others
By Therapy
Monoclonal Antibodies
-Praxbind (idarucizumab)
-Ranibizumab (Lucentis)
-Certolizumab pegol (Cimzia)
-Iodine (1311) Metuximab/ Licartin
-Beovu (brolucizumab-dbll)
-Cablivi (caplacizumab-yhdp)
-Blinatumomab/
PAB
-CroFab
-Anavip
-Anascorp
-Botulism Antitoxin Heptavalent (HBAT)
-Digibind
-DigiFab
Pipeline
-AFM13
-HPN-424
-MGD007
-Tebotelimab (MGD013)
-Bentracimab (PB2452)
-Flotetuzumab (MGD006)
-AK104
-Ozoralizumab
-Sonelokimab (ALX0761)
By Application
Cancer
Immunodeficiency
Others

13 Company Profiles
13.1 Company Snapshot
13.2 SWOT Profiles
13.3 Products and Services
13.4 Recent Developments
13.5 Financial Profile
List of Companies
AbbVie Inc
Albynx
Bristol-Myers Squibb Company
Genentech Inc
Johnson & Johnson Private Ltd
Lilly
Novartis AG
Pfizer Inc

14 Appendix
14.1 Customization Offerings
14.2 Subscription Services
14.3 Related Reports
14.4 Publisher Expertise

By Specificity
Monoclonal Antibodies
Polyclonal Antibodies
By Type
FAB
scFv
sdAb
Others
By Therapy
Monoclonal Antibodies
-Praxbind (idarucizumab)
-Ranibizumab (Lucentis)
-Certolizumab pegol (Cimzia)
-Iodine (1311) Metuximab/ Licartin
-Beovu (brolucizumab-dbll)
-Cablivi (caplacizumab-yhdp)
-Blinatumomab/
PAB
-CroFab
-Anavip
-Anascorp
-Botulism Antitoxin Heptavalent (HBAT)
-Digibind
-DigiFab
Pipeline
-AFM13
-HPN-424
-MGD007
-Tebotelimab (MGD013)
-Bentracimab (PB2452)
-Flotetuzumab (MGD006)
-AK104
-Ozoralizumab
-Sonelokimab (ALX0761)
By Application
Cancer
Immunodeficiency
Others